Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
other autoimmune candidate IMVT-1402 inches closer to a pivotal trial later this year. The results for batoclimab include “strong response rates” following an injection with the therapy, according to the US immunology specialist's CEO Pete Salzmann. Meanwhile, Immunovant has set its sights on a pivotal trial for IMVT-1402 after an investigational new drug application (IND) was cleared by the US Food and Drug Administration. The biopharma expects to initiate the study, which will also involve Graves' disease patients, by the end of this year. Immunovant has been investigating batoclimab – a monoclonal antibody – in a Phase IIa trial (NCT05907668) with Graves' disease patients who were hyperthyroid despite antithyroid therapy. Graves' disease is an autoimmune condition that leads to an overactive thyroid gland, resulting in elevated levels of two main thyroid hormones called triiodothyronine and thyroxine, also known as T3 and T4. Antithyroid drugs (ATDs) are the treatment of ch
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024PR Web
- Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus [Yahoo! Finance]Yahoo! Finance
- Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.MarketBeat
- Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024GlobeNewswire
- Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual MeetingGlobeNewswire
IMVT
Earnings
- 8/6/24 - Miss
IMVT
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 3
- 11/12/24 - Form SC
- IMVT's page on the SEC website